Lilly reports positive Phase 3 breast cancer data for imlunestrant

Eli Lilly (NYSE:LLY) reported positive Phase 3 data for its drug candidate imlunestrant as both a combination and monotherapy in the treatment of advanced breast cancer.

The study called EMBER-3, showed imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy in patients with ESR1 mutations. It also demonstrated that imlunestrant in combination with Lilly’s (LLY) Verzenio significantly reduced the risk of progression or death by 43%, compared to imlunestrant alone, in all patients, regardless of ESR1 mutation status, according to a statement.

Imlunestrant is being evaluated in patients with ER+/HER2- advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor.

Overall survival results for the study were not mature at the time of analysis. The study will continue to assess overall survival as a secondary endpoint, Lilly said.

The data will be presented Wednesday at the 2024 San Antonio Breast Cancer Symposium and published simultaneously in the New England Journal of Medicine.